14 JUL 2023 | EU | EMA confirms acceptance of Intas’ MAA for its ustekinemab (Stelara®) biosimilar Intas...
BioBlast w/e 14 Jul 23
read more
To waive or not to waive: that is the question
Will IP waivers have any impact on COVID-19 vaccine rollouts?
IP waivers alone are nowhere near enough to increase COVID-19 vaccine access for developing countries, but US support...
The COVID-19 pandemic prioritises an Australian medical products’ manufacturing road map
Background In October 2020, the Australian Government announced a $1.5 billion investment in a Modern Manufacturing...